Double-digit sales growth expected despite trade tensions
Boston Scientific shares jumped over 5% after the company raised its full-year guidance, reporting strong Q1 results and projecting up to 17% revenue growth in 2025.
Key Highlights:
- Q1 revenue: $4.66B, up 20.9%
- Net profit: $674M, up 36.2%
- EPS (adjusted): 75¢, beating forecasts by 8¢
- Growth in MedSurg (11.7%) and Cardiovascular (26.2%) segments
- Acquisitions: Bolt Medical closed, SoniVie deal announced
- Farapulse PFA system continues gaining momentum
Despite a $200M tariff impact expected in 2025 due to ongoing trade policies, Boston Scientific plans to fully offset the cost through increased revenue and cost management, with no changes to its global supply chain.
CEO Mike Mahoney credited the quarter’s success to “a highly engaged global team” and a strong product pipeline.
CFO Transition: EVP & CFO Dan Brennan will retire in June after nearly 30 years. He’ll be succeeded by Jon Monson, current SVP of investor relations.
Follow MEDWIRE.AI for insights into MedTech earnings and leadership shifts.
